A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells
새로운 종류의 TMPRSS2 억제제는 SARS-CoV-2 및 MERS-CoV 바이러스 진입을 강력하게 차단하고 인간 상피 폐 세포를 보호합니다
410
Published on
Journal: Proceedings of the National Academy of Sciences of [Category] MERS, SARS, 신약개발,
Journal: Proceedings of the National Academy of Sciences of [Category] MERS, SARS, 신약개발,
[키워드] activate
acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
addition
Antiviral
antiviral drug
block
broad-spectrum antivirals
Calu
Calu-3
calu-3 cells
camostat
can be used
cell entry
chimeric
clinical development
coronavirus
COVID-19
COVID-19 treatment
Cytopathic effect
cytopathic effects
drug
drug candidate
drug design
Drug discovery
drugs
Efficacy
epithelial
epithelial cell
epithelial cells
full-length
half-life
half-maximal effective concentration
half-maximal inhibitory concentration
help
host cell
human lung
in vivo
Influenza
influenza viruses
inhibiting
inhibitor
lead
lung
lung cell
lung tissue
mechanism
MERS-CoV
mice
Middle East
Middle East respiratory syndrome
Middle East respiratory syndrome Coronavirus
nafamostat
other coronavirus
other coronaviruses
Pathogenesis
pharmacokinetics
plasma
probe
protease
Protease inhibitor
PROTECT
Protein
PS-SCL
respiratory
respiratory syndrome coronavirus
SARS-CoV
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 infections
SARS-CoV-2 virus
selective
Serine
serine protease TMPRSS2
severe acute respiratory syndrome Coronavirus
Significance
significantly
specificity
Spike protein
stability
structure-based drug discovery
the Spike
therapeutic target
TMPRSS2
TMPRSS2 inhibitor
TMPRSS2 inhibitors
TMPRSS2 protein
treat
Treatment
Viral
viral entry
viral pathogenesis
Viral protein
viral spread
virus
[DOI] 10.1073/pnas.2108728118 PMC 바로가기 [Article Type] 410
[DOI] 10.1073/pnas.2108728118 PMC 바로가기 [Article Type] 410